Ozanimod for relapsing remitting multiple sclerosis
NIHR HSRIC
Record ID 32016001004
English
Authors' objectives:
Ozanimod is a new drug that is taken by mouth to treat patients with multiple sclerosis (MS). MS is a condition which can affect the brain and/or spinal cord. It causes a wide range of symptoms, including problems with memory and concentration, emotions, sight, speech and swallowing, arm or leg sensation and movement, bladder and bowel function and balance. More than 8 out of every 10 people with MS are diagnosed with the 'relapsing remitting' form of disease. This means that the patient will have 'attacks' of new or worsening symptoms, known as 'relapses'. Some studies have suggested that ozanimod may be able to reduce the number of 'relapses' by decreasing cells that cause inflammation.
Details
Project Status:
Completed
URL for project:
http://www.hsric.nihr.ac.uk/topics/ozanimod-for-relapsing-remitting-multiple-sclerosis/
Year Published:
2016
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Sphingosine-1-Phosphate Receptors
- Biological Products
- Multiple Sclerosis, Relapsing-Remitting
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.